[Humanized respiratory syncytial virus monoclonal antibody].
Respiratory syncytial virus remains a significant cause of severe lower respiratory tract disease in children. The risk of serious RSV illness is highest among children with prematurity, chronic lung disease and congenital heart disease. No effective vaccine and anti-viral agents have been obtained even now. Therefore, conservative therapy including respiratory aid has been a principal therapy for serious RSV disease. Recently, monthly intramuscular administration of humanized anti-RSV monoclonal antibody(palivizumab) was introduced in clinical fields in USA and Europe. Palivizumab prophylaxis has appeared to be safe and effective for prevention of serious RSV illness in premature children and those with bronchopulmonary dysplasia.
Tsutsumi
Hiroyuki
H
Department of Pediatrics, Sapporo Medical University School of Medicine.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D001997:Bronchopulmonary Dysplasia; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D051379:Mice; D000069455:Palivizumab; D015202:Protein Engineering; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000517:prevention & control; D012136:Respiratory Syncytial Viruses / Q000276:immunology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D000069455:Palivizumab